Related Experiment Video
Updated: May 4, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Progress in development of Group A Streptococcus vaccines
Yingli Song, Xiaolan Zhang, Chunmei Lu
1Department of Physiology, Harbin Medical University, Harbin 150081, China. dzhuhui@aliyun.com.
Abstract:
Streptococcus pyogenes or Group A Streptococcus (GAS) is a major Gram-positive human pathogen that causes diverse human diseases with a high morbidity and mortality worldwide. The development of an effective GAS vaccine is hindered by the occurrence of many unique GAS serotypes, the complexity of the global epidemiology of GAS infections, and safety concerns over the cross-reactivity of some antigen-specific antibodies with human tissues and proteins. Although no licensed GAS vaccine is available, a number of candidate vaccines have been or are being evaluated in laboratory or in clinical trials. This minireview provides brief information on the progress and difficulty in the development of GAS vaccines.
Related Concept Videos
Vaccine Production
Clinical Significance of Antibiotic Resistance
Microorganisms in Medicine and Therapeutics
Development of Antibiotic Resistance
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Staphylococcal Skin Infections

